Antidepressant dosage form

Abstract

A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of time in a therapeutically responsive dose to produce antidepressant therapy.

We claim: 
     
         1 . A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an, extended period of time in a therapeutically responsive dose to produce antidepressant therapy, the dosage form comprising:
 (a) a wall comprising at least in part a composition permeable to the passage of fluid, but not to 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol, which wall surrounds;   (b) a compartment comprising a first layer and a second layer;   (c) a drug composition in the first layer of the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol and a hydroxypropylalkylcellulose wherein said alkyl is of 1 to 3 carbons or a hydroxyalkylcellulose wherein said alkyl is of 1 to 3 carbons;   (d) a displacement composition in the second layer of the compartment comprising an osmotically active compound; and   (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form.   
     
     
         2 . A dosage form having controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of time in a therapeutically responsive dose to produce antidepressant therapy, the dosage form comprising:
 (a) a wall comprising at least in part a composition permeable to the passage of fluid, but not to 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol, which wall surrounds;   (b) a compartment comprising a first layer and a second layer;   (c) a drug composition in the first layer of the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol and a poly(ethylene oxide) having a molecular weight of 100,000 to 600,000;   (d) a displacement composition in the second layer of the compartment comprising an osmotically active compound and a poly(ethylene oxide) comprising the repeating unit (—CH 2 —CH 2 —O—) n , wherein n is a positive whole number of 50,000 to 300,000; and   (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form.   
     
     
         3 . A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of time in a therapeutically responsive dose to produce antidepressant therapy, the dosage form comprising:
 (a) a wall comprising at least in part a composition permeable to the passage of fluid, but not to 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol, which wall surrounds;   (b) a compartment comprising a first layer and a second layer;   (c) a drug composition in the first layer of the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol and a hydroxyalkylcellulose wherein said alkyl is of 1 to 3 carbons;   (d) a displacement composition in the second layer of the compartment comprising an osmotically active compound; and   (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form.